29Oct 2018
Holy Stone Healthcare Co., Ltd.‘s new drug for colorectal cancer, CA102N, has received from US FDA the IND approval for conducting phase I clinical trial.
read more
26Jun 2018
Holy Stone Healthcare Co., Ltd. attended 2018 BIO International Convention in Boston, USA on June 4-7.
read more
13Apr 2018
Holy Stone Healthcare participates in the Chicago 2018 AACR Annual Meeting (2018/4/14-4/18) poster presentation. Dr. Eskouhie Tchaparian will promote the company’s new drug, CA102N, targeting colorectal cancer.
read more

Vision & Mission

We are committed to developing lifesaving therapeutics and targeted delivery technologies to improve the quality of life of patients worldwide. Our mission is to create innovative therapeutic products based on hyaluronic acid using our know-how and experience to address unmet clinical needs with superior tolerability and efficacy.

Products

We are focused on development of new drugs and medical devices, especially hyaluronic acid related therapeutic products.